Abizer Gaslightwala - 06 Mar 2025 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Role: Director
Signature: /s/ Torsten Hombeck, as Attorney-in-Fact
Issuer symbol: AKTX
Transactions as of: 06 Mar 2025
Net transactions value: +$449,998
Form type: 4
Filing time: 10 Mar 2025, 17:00:03 UTC
Previous filing: 07 Feb 2025
Next filing: 24 Mar 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKTX	American Depositary Shares representing Ordinary Shares	Award	$149,999	+133,928	+282%	$1.12	181,428	06 Mar 2025	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKTX	Series A Warrants (Right to Buy)	Award	$149,999	+133,928		$1.12	133,928	06 Mar 2025	American Depositary Shares representing Ordinary Shares	133,928	$0.8700	Direct	F1, F2
transaction	AKTX	Series B Warrants (Right to Buy)	Award	$149,999	+133,928		$1.12	133,928	06 Mar 2025	American Depositary Shares representing Ordinary Shares	133,928	$0.8700	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.
F2	On March 6, 2025, the Reporting Person acquired 133,928 ADS and accompanying Series A and Series B warrants to purchase up to 267,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant.